Integrated Novel Clinical Decision Support System (CDSS) in a Computerized Physician Order Entry System

NCT ID: NCT00904072

Last Updated: 2009-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to understand the impact of CDSS by knowing the prescribers actions to the CDSS, also the influence of prescribing error announced by pharmacists.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. To assess the sensitivity of the CDSS which could identify some specific prescribing errors (ex: duplication of drugs, dosage that exceed the maximum dose,prescribes drugs that have drug-drug interactions).
2. To identify what kind of drugs are most likely to cause duplication use by the physicians, and what kind of drugs are most likely to exceed the maximum dosage, also to know what kind of drugs are most likely to cause drug-drug interaction that physicians encounter during prescribing.
3. To evaluate the percentage of physician acceptance of the prescribing errors identify by the CDSS.
4. What's the impact of CDSS on pharmacist announced prescribing error.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Evaluate the Impact of the CDSS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

accepted

The suggestions provided by the CDSS which were accepted by the physicians.

No interventions assigned to this group

denied

The suggestions provided by the CDSS which were denied by the physicians.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The prescriptions which induced the alert windows pop out.

Exclusion Criteria

* The prescriptions which not induced the alert windows pop out.
Minimum Eligible Age

1 Day

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Grauduate Institute of Clinical Pharmacy, College of medicine, National Taiwan university, Grauduate Institute of Clinical Pharmacy

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fe-Lin Lin Wu, Associate Professor

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Taiwan University Hospital Taipei, Taiwan

Taipei, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fe-Lin Lin Wu, Associate Professor

Role: CONTACT

886-2-23123456 ext. 88389

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fe-Lin Lin Wu

Role: primary

886-2-23123456 ext. 88389

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20080306OR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Pharmacist Impact Study
NCT07269002 COMPLETED NA